Phase II study of thymosin fraction 5 in the treatment of metastatic renal cell carcinoma.
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013947:Thymosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
C033782:thymosin fraction 5; D013947:Thymosin